CELEX: 32021M10442
Language: en
Date: 2021-10-06 00:00:00
Title: Commission Decision of 06/10/2021 declaring a concentration to be compatible with the common market (Case No COMP/M.10442 - ADVENT INTERNATIONAL / SOBI) according to Council Regulation (EC) No 139/2004 (Only the English text is authentic)

EUROPEAN COMMISSION
                                                                 Brussels, 6.10.2021
                                                                 C(2021) 7350 final
                                                                                 PUBLIC VERSION
                                                                 Advent International Corporation
                                                                 Prudential Tower
                                                                 800 Boylston Street, Suite 3300
                                                                 MA 02199 Boston
                                                                 United States of America
Subject:         Case M.10442 - ADVENT INTERNATIONAL / SOBI
                 Commission decision pursuant to Article 6(1)(b) of Council Regulation
                 (EC) No 139/20041 and Article 57 of the Agreement on the European
                                    2
                 Economic Area
Dear Sir or Madam,
1.      On 14 September 2021, the European Commission received notification of a proposed
        concentration pursuant to Article 4 of the Merger Regulation by which Advent
        International Corporation (‘Advent’, USA) acquires within the meaning of Article
        3(1)(b) of the Merger Regulation sole control of the whole of Swedish Orphan
        Biovitrum AB (‘Sobi’, Sweden) by way of public bid announced on 2 September
        2021.3
2.      The business activities of the undertakings concerned are:
             Advent is a private equity investor based in Boston, USA. Advent focuses on the
              acquisition of equity stakes and the management of investment funds in various
              sectors, including healthcare, industrial, technology, retail, consumer and leisure,
              and business and financial services.
             Sobi is headquartered in Stockholm, Sweden and is listed on the Nasdaq
              Stockholm stock exchange. Sobi is an originator pharmaceutical company
              focussing on the treatment of rare diseases, with its principal areas of focus on
              treatments in haematology and immunology.
1       OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’). With effect from 1 December 2009, the Treaty on
        the Functioning of the European Union (‘TFEU’) has introduced certain changes, such as the
        replacement of ‘Community’ by ‘Union’ and ‘common market’ by ‘internal market’. The terminology
        of the TFEU will be used throughout this decision.
2       OJ L 1, 3.1.1994, p. 3 (the ‘EEA Agreement’).
3       Publication in the Official Journal of the European Union No C 384, 22.9.2021, p. 4.
Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË
Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.
 ---pagebreak--- 3. After examination of the notification, the European Commission has concluded that
   the notified operation falls within the scope of the Merger Regulation and of
   paragraph 5(c) of the Commission Notice on a simplified procedure for treatment of
   certain concentrations under Council Regulation (EC) No 139/2004.4
4. For the reasons set out in the Notice on a simplified procedure, the European
   Commission has decided not to oppose the notified operation and to declare it
   compatible with the internal market and with the EEA Agreement. This decision is
   adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of
   the EEA Agreement.
                                                  For the Commission
                                                  (Signed)
                                                  Olivier GUERSENT
                                                  Director-General
4  OJ C 366, 14.12.2013, p. 5.
                                              2